Belite Bio, Inc
BLTE
주식 순위
#2984
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
주가
$152.78
시가총액
$6.15B
변동 (1일)
-1.08%
변동 (1년)
66.06%
국가
US
거래 Belite Bio, Inc (BLTE)
카테고리
Healthcare
Belite Bio, Inc (BLTE)의 주가 이력
최고 종가: $154.24 (2026-10-01 기준)
최저 종가: $10.59 (2022-04-01 기준)
최저 종가: $10.59 (2022-04-01 기준)
Belite Bio, Inc의 주가 이력 (2022 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 1.17% |
| 2025 | 137.93% |
| 2024 | 45.90% |
| 2023 | 43.40% |
| 2022 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
